Ireland - English - HPRA (Health Products Regulatory Authority)

gsk vaccines s.r.l. - meningococcal group c oligosaccharide; corynebacterium diphtheriae crm197 protein - suspension for injection in pre-filled syringe - 10 - meningococcal vaccines; other meningococcal polyvalent purified polysaccharides antigen - meningococcal vaccines - active immunisation of children from 2 months of age, adolescents and adults, for the prevention of invasive disease caused by neisseria meningitidis group c.

European Union - English - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a. - split influenza virus, inactivated, containing antigen*: a/california/7/2009 (h1n1)v like strain (x-179a)*propagated in eggs. - influenza, human; immunization; disease outbreaks - influenza vaccines - prophylaxis of influenza in an officially declared pandemic situation. pandemic influenza vaccine should be used in accordance with official guidance

European Union - English - EMA (European Medicines Agency)

gsk vaccines s.r.l. - outer membrane vesicles from neisseria meningitidis group b (strain nz 98/254), recombinant neisseria meningitidis group b fhbp fusion protein, recombinant neisseria meningitidis group b nada protein, recombinant neisseria meningitidis group b nhba fusion protein - meningitis, meningococcal - meningococcal vaccines - active immunisation against invasive disease caused by neisseria meningitidis serogroup-b strains.,

European Union - English - EMA (European Medicines Agency)

nanotherapeutics bohumil, s.r.o. - whole virion influenza vaccine, inactivated containing antigen of strain a/california/07/2009 (h1n1)v - disease outbreaks; influenza, human; immunization - vaccines - prophylaxis of influenza caused by a(h1n1)v 2009 virus.celvapan should be used in accordance with official guidance.

European Union - English - EMA (European Medicines Agency)

sanofi pasteur s.a. - split influenza virus, inactivated, containing antigen*: a/california/7/2009 (h1n1)v like strain (x-179a)*propagated in eggs. - influenza, human; immunization; disease outbreaks - vaccines - prophylaxis of influenza in an officially declared pandemic situation.pandemic influenza vaccine should be used in accordance with official guidance.

European Union - English - EMA (European Medicines Agency)

intervet international bv - inactivated whole avian influenza virus antigen of h5n2 subtype (strain a/duck/potsdam/1402/86) - immunologicals for aves - chicken - for active immunisation of chickens against avian influenza type a, subtype h5.efficacy has been evaluated on the basis of preliminary results in chickens. reduction of clinical signs, mortality and excretion of virus after challenge were shown by three weeks after vaccination.serum antibodies could be expected to persist for at least 12 months after administration of two doses of vaccine.

European Union - English - EMA (European Medicines Agency)

intervet international bv - inactivated whole avian influenza virus antigen of h5 subtype (strain h5n6, a/duck/potsdam/2243/84) - immunologicals for aves - chicken - for active immunisation of chickens against avian influenza type a, subtype h5.reduction of clinical signs, mortality and excretion of virus after challenge with a virulent h5n1 strain, were shown by two weeks after a single dose vaccination.serum antibodies have been shown to persist in chickens for at least 7 months and studies performed with other vaccine strains show that serum antibodies would be expected to persist in chickens for at least 12 months after administration of two doses of vaccine.

European Union - English - EMA (European Medicines Agency)

intervet international bv - inactivated whole avian influenza virus antigen of h7n1 subtype (strain, a/ck/italy/473/99) - immunologicals for aves - chicken; ducks - for active immunisation of chickens and ducks against avian influenza type a, subtype h7n1.efficacy has been evaluated on the basis of preliminary results in chickens and ringed teals.in chickens, reduction of clinical signs, mortality, excretion and transmission of virus after challenge were shown by two weeks after a single dose vaccination.in ducks, reduction of excretion and transmission of virus after challenge were shown by two weeks after a single dose vaccination.although it has not been investigated with this particular ai vaccine strain, studies performed with other strains show that protective levels of serum antibody titres would be expected to persist in chickens for at least 12 months after administration of two doses of vaccine. the duration of immunity in ducks is unknown.

European Union - English - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a. - a/indonesia/05/2005 (h5n1) like strain used (pr8-ibcdc-rg2) - influenza, human; immunization; disease outbreaks - vaccines - active immunisation against h5n1 subtype of influenza-a virus.this indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of vaccine prepared with h5n1 subtype strains.prepandrix should be used in accordance with official guidance.

European Union - English - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a.  - pandemic influenza vaccine (h5n1) (split virion, inactivated, adjuvanted)  - influenza, human; immunization; disease outbreaks - vaccines - prophylaxis of influenza in an officially declared pandemic situation.pandemic-influenza vaccine should be used in accordance with official guidance.